Pms47 - Cost-Effectiveness of Tofacitinib Compared With Adalimumab in the Treatment of Moderate to Severe Rheumatoid Arthritis in Iran
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1761
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV